MRI perfusion in determining pseudoprogression in patients with glioblastoma. - sprookjes - yvandenbroek - TriplyDB

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

http://www.wikidata.org/entity/Q36585386

about

Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images Advanced magnetic resonance imaging methods for planning and monitoring radiation therapy in patients with high-grade glioma Recent Application of Advanced MR Imaging to Predict Pseudoprogression in High-grade Glioma Patients Treatment-related brain tumor imaging changes: So-called "pseudoprogression" vs. tumor progression: Review and future research opportunities Use of high-resolution volumetric MR spectroscopic imaging in assessing treatment response of glioblastoma to an HDAC inhibitor Characterization of pseudoprogression in patients with glioblastoma: is histology the gold standard?ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain.Detecting tumor progression in glioma: Current standards and new techniques.Analysis of heterogeneity in T2-weighted MR images can differentiate pseudoprogression from progression in glioblastoma.Evaluation of pseudoprogression in patients with glioblastoma multiforme using dynamic magnetic resonance imaging with ferumoxytol calls RANO criteria into question.Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.Delayed contrast extravasation MRI: a new paradigm in neuro-oncology Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis.Alterations of the Blood-Brain Barrier and Regional Perfusion in Tumor Development: MRI Insights from a Rat C6 Glioma Model The diagnostic performance of perfusion MRI for differentiating glioma recurrence from pseudoprogression: A meta-analysis.Quantitative MRI for analysis of peritumoral edema in malignant gliomas Pretreatment Dynamic Susceptibility Contrast MRI Perfusion in Glioblastoma: Prediction of EGFR Gene Amplification.Diffusion and perfusion MRI to differentiate treatment-related changes including pseudoprogression from recurrent tumors in high-grade gliomas with histopathologic evidence Vascular Reactivity Maps in Patients with Gliomas Using Breath-Holding BOLD fMRI.Misleading early blood volume changes obtained using ferumoxytol-based magnetic resonance imaging perfusion in high grade glial neoplasms treated with bevacizumab.Dynamic Susceptibility Contrast-MRI Quantification Software Tool: Development and Evaluation.Pseudoprogression and pseudoresponse in the management of high-grade glioma : optimal decision timing according to the response assessment of the neuro-oncology working group.Mean cerebral blood volume is an effective diagnostic index of recurrent and radiation injury in glioma patients: A meta-analysis of diagnostic test.Combined use of susceptibility weighted magnetic resonance imaging sequences and dynamic susceptibility contrast perfusion weighted imaging to improve the accuracy of the differential diagnosis of recurrence and radionecrosis in high-grade glioma pa Incidence of pseudoprogression in low-grade gliomas treated with radiotherapy.MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives.MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.Technical Pitfalls of Signal Truncation in Perfusion MRI of Glioblastoma.Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges.Apparent transverse relaxation (R2∗) on MRI as a method to differentiate treatment effect (pseudoprogression) versus progressive disease in chemoradiation for malignant glioma.Perfusion MRI in the Evaluation of Suspected Glioblastoma Recurrence.Comment on "The role of imaging in the management of progressive glioblastoma. A systematic review and evidence-based clinical practice guideline" [J Neurooncol 2014; 118:435-460].Identification of a candidate biomarker from perfusion MRI to anticipate glioblastoma progression after chemoradiation.Evaluation of recurrent high-grade gliomas treated with bevacizumab: A preliminary report of 3D pseudocontinuous artery spin labeling.Interobserver variability in the radiological assessment of magnetic resonance imaging (MRI) including perfusion MRI in glioblastoma multiforme.Survival after radiation therapy for high-grade glioma

P2860

Q26743358-0E8981B3-781B-4D1D-871A-022B86DFFAB9 Q26826862-517F893E-659D-4C49-A246-C7B341E7F013 Q28066044-A1414190-C052-4E27-B1AE-5FAE5700BCE5 Q30627773-BCB9B5C7-9E8F-49FE-8454-70E60FB820A1 Q30838169-2078F56D-7B6B-40B4-97AE-74CB3C478A94 Q30937034-05CAE715-A89F-4D2B-BC67-82F21F083295 Q30938805-B5701742-AEE5-4484-A757-0AF6AE6B45CC Q31132701-9C40BA88-8640-43B3-A006-965E1FFE0BE4 Q33698886-CA3E625A-471C-42A1-BED9-9226C72DA100 Q33894461-9106E68C-B5C1-4EB4-996A-8B678CE50DBD Q35771783-AF26F240-677C-4839-85F7-31605B3FAE50 Q35788925-14F0208A-A967-4242-BA27-93C1DB2323AC Q35811181-0B75EB34-C2B9-4D69-A9E7-C2DE41203EF6 Q36097886-9AE9E805-441D-4F86-8633-F7AA08EB3DE4 Q36231584-98923CB7-3446-4434-935A-B985EC309066 Q36308850-D446822D-B8E4-487F-B5A8-71694CE78339 Q36380888-9E20D87D-80AD-4DD1-BC04-252CADFD56F7 Q36459981-9FD17E35-F794-481C-801E-D5B05E6CB9B5 Q36515232-6FE2719C-4975-4199-9B83-F56115BC474D Q37380167-A4721C75-5838-4738-85B3-0E71C79FA208 Q37523107-710A3B19-1616-451D-BB73-464C1DEB7D4C Q37565951-EABFC821-8921-4C37-9B5E-96553C2F4B42 Q37591724-2EAC7CD3-A4AF-4539-A2E4-CF82F66F0F1F Q37716593-81F72595-5A1B-4D25-98D5-F429A80AFBE7 Q37746319-D7D5F331-2EE2-4898-B25F-D13CD2285486 Q38814458-D7CAF1CB-777B-4D92-A10E-06DF5C80B803 Q39312420-E0D68DAE-D7BE-413E-88DA-F7B505439BFD Q41218067-A7EB4D0B-3629-4607-BC21-157518715C6C Q42386456-F0E7C2C5-2210-4236-B9CD-886C194D2D27 Q43376098-EFEDA6AB-257B-48A0-AF5C-145D3670A5E0 Q47385832-0B2A3F32-1CA5-4980-BA1C-7368C747A53B Q48213178-9939AF30-60E4-4992-A7F8-CA303A536D0C Q48467664-F4D3F796-C778-4B0F-A192-AD969FBD4EC4 Q48930260-BA4B6ED2-D962-4693-8A15-93FE5BBE2FF0 Q55458839-1BE614F2-DED1-481A-900B-78D201D021EB Q55459134-7ED51EA4-BD52-423C-8E05-D613FACA5F29 Q58544790-8C02BE1D-0B24-4858-BFB2-00FF2C1BC729

P2860

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

http://www.wikidata.org/entity/Q36585386

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@ast

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@en

type

label

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@ast

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@en

prefLabel

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@ast

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@en

P1433

Q36585386-8D353B14-B953-4F6C-ADC9-10ED989249C9

P1476

Q36585386-2F9BF3EB-F1E0-414B-A5C9-15AA63D7E550

P2093

Q36585386-0CA353F4-22B2-41FF-AF52-DB28B6C9AB7D

Q36585386-6FDD234B-C038-462D-9B31-019C5FA93DCE

Q36585386-A43925F3-B657-40D1-8767-43BEED7A2D68

Q36585386-AA14D28C-9D4A-461A-8EC9-960255DBFCA9

Q36585386-AC72F251-5135-4F6C-ACD7-65BF54A7A315

Q36585386-C591355B-C1EF-47AD-A45A-7C8B7E9E9193

Q36585386-CD3CE339-B715-428A-B985-F2B330AA19E8

Q36585386-D416FDE6-B90E-47E9-A33A-7DB61C8335BB

Q36585386-DFC84795-C33F-46E2-A0B9-A1C42C4299B1

P2860

Q36585386-0B996C7E-6E0B-47DD-A822-C7886F6CB41D

Q36585386-0F4D6824-9716-4A96-831C-F86D4E4471A8

Q36585386-0F782F8D-5DD4-4FA5-9A8F-6B0F9FF62C55

Q36585386-12C7A93F-8B2C-4813-B5A4-6DF2AF0B1E21

Q36585386-16714A48-8E02-41C8-A788-D7415230A0AE

Q36585386-2B1E1722-D5ED-4CDC-9765-91A6EAB620C7

Q36585386-2E24C820-274D-4704-8FC7-120D1B6D7F49

Q36585386-2E8779DC-752F-48A5-AC4A-108A9E5A4198

Q36585386-32DC8FD4-F0FF-4149-9C77-D4FFF27FF251

Q36585386-3767C1D0-83C3-4F4C-B980-30BC1421D369

P304

Q36585386-B5986C44-0C86-4027-86D7-3D0C97D8EA94

P31

Q36585386-AD6B1DE3-4FFC-4B5C-8086-C882D469A8CA

P356

Q36585386-907A7157-9838-4229-ADF2-9C69CB970DD2

P433

Q36585386-C712E304-FC53-4A85-B0F7-A987DAA3B29A

P478

Q36585386-62D1A8A8-5419-46C8-9434-935BD746A40F

P577

Q36585386-4609C2C0-6759-48C0-BB60-E8CCBCE18427

P698

Q36585386-47332896-F1BF-4DC1-B668-ED0152AD9D7A

P932

Q36585386-EF4C4912-6336-4232-93D1-85CD0A949F50

P356

J.CLINIMAG.2012.02.016

P1433

Clinical Imaging

P1476

MRI perfusion in determining pseudoprogression in patients with glioblastoma.

@en

P2093

Ajay Gupta

http://www.w3.org/2001/XMLSchema#string

Akash D Shah

http://www.w3.org/2001/XMLSchema#string

Antonio M Omuro

http://www.w3.org/2001/XMLSchema#string

Jerome J Graber

http://www.w3.org/2001/XMLSchema#string

Kathryn Beal

http://www.w3.org/2001/XMLSchema#string

Robert J Young

http://www.w3.org/2001/XMLSchema#string

Timothy A Chan

http://www.w3.org/2001/XMLSchema#string

Weiji Shi

http://www.w3.org/2001/XMLSchema#string

Zhigang Zhang

http://www.w3.org/2001/XMLSchema#string

P2860

Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

Dynamic magnetic resonance perfusion imaging of brain tumors.

Brain MRI: tumor evaluation.

Pitfalls in the diagnosis of brain tumours.

Intraaxial brain masses: MR imaging-based diagnostic strategy--initial experience.

Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas.

Value of dynamic susceptibility contrast magnetic resonance imaging in the evaluation of intracranial tumors.

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

P304

41-49

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CLINIMAG.2012.02.016

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23151413

http://www.w3.org/2001/XMLSchema#string

P932

4755513

http://www.w3.org/2001/XMLSchema#string